Orlistat is a clinically available anti-obesity drug that acts as inhibitor of gastric and pancreatic lipase and has been shown to block the absorption of dietary fats of about 30% at the therapeutic oral dosage of 120 mg per three times a day. Here, PNLIP is linked to obesity due to melanocortin 4 receptor deficiency.